Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chart: Tally Of Trouble: The Biggest Pharmaceutical Product Liability Cases

You may also be interested in...



GlaxoSmithKline Hires Former FDA Top Lawyer Dan Troy As General Counsel

Former FDA Chief Counsel Daniel Troy will once again be leading a team of lawyers with a drug regulatory focus

Wyeth loses product liability suit

Nevada jury finds that Wyeth's hormone replacement drugs Prempro and Premarin caused breast cancer in three women and awarded them a total of $134.5 million in compensatory damages. In its Oct. 10 verdict, the jury reportedly said Wyeth concealed a material fact about the safety of the drugs and acted with fraud and malice. The jury was to decide Oct. 12 if Wyeth should also pay punitive damages. The company has won six previous cases - three suits were dismissed, a judge overturned a jury verdict for plaintiffs in one case, and two resulted in verdicts for Wyeth (1"The Pink Sheet" July 9, 2007, p. 23). Approximately 5,200 suits have been filed in federal and state courts on behalf of about 8,400 women...

Risperdal Gets Approval For Adolescents; FDA Concerns Delay Zyprexa

Johnson & Johnson's Risperdal beat Lilly's Zyprexa as the first drug into the adolescent schizophrenia and bipolar I disorder market, with FDA approval for risperidone for the two indications Aug. 22

UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel